Michelle Geddes

1.5k total citations
30 papers, 840 citations indexed

About

Michelle Geddes is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Oncology. According to data from OpenAlex, Michelle Geddes has authored 30 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 11 papers in Public Health, Environmental and Occupational Health and 9 papers in Oncology. Recurrent topics in Michelle Geddes's work include Hematopoietic Stem Cell Transplantation (14 papers), Acute Myeloid Leukemia Research (12 papers) and Acute Lymphoblastic Leukemia research (11 papers). Michelle Geddes is often cited by papers focused on Hematopoietic Stem Cell Transplantation (14 papers), Acute Myeloid Leukemia Research (12 papers) and Acute Lymphoblastic Leukemia research (11 papers). Michelle Geddes collaborates with scholars based in Canada, United States and Italy. Michelle Geddes's co-authors include Jan Storek, Douglas A. Stewart, Faisal Khan, Mary Lynn Savoie, Nizar J. Bahlis, M. Ahsan Chaudhry, James A. Russell, Diana Quinlan, Eva Buiatti and Bertrand Huard and has published in prestigious journals such as Blood, European Journal of Cancer and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Michelle Geddes

29 papers receiving 836 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michelle Geddes Canada	14	535	223	212	167	111	30	840
Adisak Tantiworawit Thailand	15	407 0.8×	83 0.4×	67 0.3×	232 1.4×	117 1.1×	129	894
Judit Müller Hungary	14	96 0.2×	82 0.4×	36 0.2×	204 1.2×	60 0.5×	47	525
Matthias Dürken Germany	17	430 0.8×	139 0.6×	139 0.7×	97 0.6×	98 0.9×	35	778
S Yokomaku Japan	11	372 0.7×	278 1.2×	148 0.7×	117 0.7×	48 0.4×	23	611
Anna Kohn Italy	18	66 0.1×	79 0.4×	160 0.8×	65 0.4×	721 6.5×	50	1.2k
Françoise Isnard France	14	260 0.5×	237 1.1×	24 0.1×	79 0.5×	450 4.1×	29	1.0k
Gowtham K. Annarapu United States	11	97 0.2×	24 0.1×	74 0.3×	103 0.6×	36 0.3×	22	393
R Duquesnoy United States	16	117 0.2×	98 0.4×	320 1.5×	40 0.2×	103 0.9×	41	832
Katjana Orlopp Germany	10	166 0.3×	245 1.1×	11 0.1×	63 0.4×	149 1.3×	17	567
Sara Renna Italy	17	41 0.1×	37 0.2×	150 0.7×	124 0.7×	449 4.0×	54	787

Countries citing papers authored by Michelle Geddes

Since Specialization

Citations

This map shows the geographic impact of Michelle Geddes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Geddes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Geddes more than expected).

Fields of papers citing papers by Michelle Geddes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Geddes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Geddes. The network helps show where Michelle Geddes may publish in the future.

Co-authorship network of co-authors of Michelle Geddes

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Geddes. A scholar is included among the top collaborators of Michelle Geddes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Geddes. Michelle Geddes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buckstein, Rena, Karen Yee, Michelle Geddes, et al.. (2023). The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma. 64(3). 651–661. 3 indexed citations

Brandwein, Joseph, et al.. (2020). Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study.. PubMed. 10(4). 124–133. 22 indexed citations

Leitch, Heather A., Rena Buckstein, Nancy Zhu, et al.. (2018). Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. Leukemia Research. 74. 21–41. 24 indexed citations

Cornely, Oliver A., Michael Robertson, Shariq Haider, et al.. (2017). Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. Journal of Antimicrobial Chemotherapy. 72(12). 3501–3501. 9 indexed citations

Lam, Wilson, Jan Storek, Haocheng Li, Michelle Geddes, & Andrew Daly. (2017). Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti‐thymocyte globulin myeloablative conditioning. Transplant Infectious Disease. 19(3). 11 indexed citations

Buckstein, Rena, Richard A. Wells, Nancy Zhu, et al.. (2016). Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements. Blood. 128(22). 3192–3192.

Parmar, Ambica, Heather A. Leitch, Richard A. Wells, et al.. (2015). Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study. Blood. 126(23). 1701–1701. 4 indexed citations

Russell, James A., Tyler Williamson, M. Ahsan Chaudhry, et al.. (2013). Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation. Biology of Blood and Marrow Transplantation. 19(9). 1381–1386. 27 indexed citations

Brandwein, Joseph, Michelle Geddes, Jeannine Kassis, et al.. (2013). Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus.. PubMed. 3(2). 141–64. 12 indexed citations

10.

Jones, David T., Loree Larratt, Robert Turner, et al.. (2013). Progressive vs Non-Progressive Onset of Chronic GVHD After ATG Prophylaxis Is Highly Predictive of Outcome. Biology of Blood and Marrow Transplantation. 19(2). S327–S327. 1 indexed citations

11.

Daly, Andrew, Mary Lynn Savoie, Michelle Geddes, et al.. (2012). Fludarabine, Busulfan, Antithymocyte Globulin, and Total Body Irradiation for Pretransplantation Conditioning in Acute Lymphoblastic Leukemia: Excellent Outcomes in All but Older Patients with Comorbidities. Biology of Blood and Marrow Transplantation. 18(12). 1921–1926. 17 indexed citations

12.

Ng, Ella S.M., M. Ahsan Chaudhry, Judy Wu, et al.. (2011). Development and Validation of a Test Dose Strategy for Once-Daily i.v. Busulfan: Importance of Fixed Infusion Rate Dosing. Biology of Blood and Marrow Transplantation. 18(2). 295–301. 31 indexed citations

13.

Hoegh-Petersen, Mette, Dawn Goodyear, Michelle Geddes, et al.. (2010). High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Bone Marrow Transplantation. 46(8). 1104–1112. 32 indexed citations

14.

Williamson, Tyler, M. Ahsan Chaudhry, Mary Lynn Savoie, et al.. (2010). Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG. Bone Marrow Transplantation. 46(8). 1077–1083. 11 indexed citations

15.

Russell, James A., William Irish, M. Ahsan Chaudhry, et al.. (2009). The Addition of 400 cGY Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces Relapse Without Affecting Nonrelapse Mortality in Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 16(4). 509–514. 49 indexed citations

16.

Geddes, Michelle, Diana Quinlan, M. Ahsan Chaudhry, et al.. (2008). High Busulfan Exposure Is Associated with Worse Outcomes in a Daily i.v. Busulfan and Fludarabine Allogeneic Transplant Regimen. Biology of Blood and Marrow Transplantation. 14(2). 220–228. 101 indexed citations

17.

Geddes, Michelle & Jan Storek. (2007). Immune reconstitution following hematopoietic stem-cell transplantation. Best Practice & Research Clinical Haematology. 20(2). 329–348. 68 indexed citations

18.

Russell, James A., Mary Lynn Savoie, A. Robert Turner, et al.. (2007). Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine, 400 CGY Total-Body Irradiation, and Thymoglobulin. Biology of Blood and Marrow Transplantation. 13(7). 814–821. 61 indexed citations

19.

Geddes, Michelle, Ahsan Chaudhry, Mary Lynn Savoie, et al.. (2006). High Busulfan Exposure Is Associated with Worse Outcome in a Daily IV Busulfan and Fludarabine Transplant Regimen.. Blood. 108(11). 313–313. 2 indexed citations

20.

Crocetti, Emanuele, et al.. (1998). The use of complementary therapies by breast cancer patients attending conventional treatment. European Journal of Cancer. 34(3). 324–328. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact